The use of hybrid molecules has become one of the most significant approaches in new cytotoxic drug design. This study describes synthesis and characterization of conjugates consisting of two well-known and characterized chemotherapeutic agents: methotrexate (MTX) and epirubicin (EPR). The synthesized conjugates combine two significant anticancer strategies: combinatory therapy and targeted therapy. These two drugs were chosen because they have different mechanisms of action, which can increase the anticancer effect of the obtained conjugates. MTX, which is a folic acid analog, has high cytotoxic properties and can serve as a targeting moiety that can reach folate receptors (FRs) overexpresing tumor cells. Combination of nonselective drugs such as EPR with MTX can increase the selectivity of the obtained conjugates, while maintaining the high cytotoxic properties.
IntroductIon
Most cytostatic agents exhibit serious side effects due to their lack of selectivity for cancer cells. Current efforts are focused on more specific drug design. An intensively exploited technique in new anticancer drug discovery is a hybrid molecule formation where two or more active molecules are linked together [7, 20] . The conjugation of a cytotoxic drug with the leading molecule can help to overcome the limitation of non-selectivity. The obtained conjugated drug should show higher selectivity for cancer cells resulting in lower toxicity for normal cells and tissues [14, 27] . Tumor cells intensive divisions have a high demand for nucleotides that are essential during DNA replication. For this reason, a significant number of cancer cells show overexpression of folate receptors (FR-positive cancers), which makes these receptors an attractive target in selective drug delivery [9] . Methotrexate (MTX) can serve as a targeting moiety that not only has the ability to reach FR-positive tumor cells but also shows high cytostatic properties [12, 31] . Another critical issue in effective drug design is cancer cells cytotoxic resistance. To overcome this problem, combinatory therapy utilizing agents targeting several different, often unrelated pathways, was applied. A hybrid molecule containing two or more drugs is advantageous because it provides a way for synergistic therapeutic action. This strategy involves the development of multifunctional drugs with more than one molecular target [25] . Methotrexate is one of the most widely used cytotoxic drugs in the treatment of several types of cancer such as leukemia, lymphoma and breast cancer [2] . This drug is a folic acid (FA) antimetabolite. Folic acid derivatives (folates) are involved in the transport of carbon groups that are required during purines and pyrimidines synthesis. MTX belongs to dihydrofolate reductase (DHFR) inhibitors and possesses greater affinity to DHFR than FA [25, 36] . Interaction between MTX and DHFR induces a deficiency of reduced folate cofactors in the cell, which inhibit cofactor-dependent enzymes like glycineamide ribonucleotide (GAR) transformylase, aminoimidazolecarboximide ribonucleotide (AICAR) transformylase and thymidylate synthase (TS). Inhibition of these enzymes results in DNA synthesis retardation [10, 28] . We distinguish three groups of MTX transporters in mammalian cells: reduced folate carrier (RFC), proton-coupled folate transporter (PCFT) and folate receptors (FRs). RFC belongs to antiporters and utilizes the organic phosphate gradient to transport folates through the cell membrane whereas PCFT exploits the proton gradient to that purpose. Folate receptors (FRs) are expressed at the cell surface as glycosylphosphatidylinositol-anchored glycoproteins. These receptors have the ability to bind MTX and transport this molecule into the cell through receptor-mediated endocytosis [2, 32, 35] . Most efficient MTX and folates transport occurs through reduced folate carrier (RFC), whereas FA shows low affinity to these transporters [35] . All of these molecules can undergo cellular uptake exploiting folate receptors [2, 32] . MTX, as well as FA, after internalization can undergo polyglutamination, which extends the residence time of these molecules inside the cell [25, 32] . Both carboxylic groups of MTX are utilized in conjugate design since MTX with a modified α or γ carboxylic group is able to be transported through FR. However, free α-carboxylic group is preferable [9, 17] . Epirubicin (EPR) is a semisynthetic, anthracycline antibiotic, derivative of doxorubicin. EPR consists of hydrophobic aglycone attached by β-glycosidic bond to an aminosugar ring [3, 16] . Best known mechanisms of EPR action are:
• intercalation into DNA, which interferes with replication and transcription of DNA; • generation of free radicals, which leads to biomolecules and DNA damage and lipid peroxidation; 
Full
• inhibition of topoisomerase II, which causes DNA damage and induction of apoptosis [5, 18, 24, 29] .
Epirubicin is characterized by high cytotoxicity, but a nonspecific drug delivery results in various side effects [34] . The aminosugar is intensively exploited to produce epirubicin conjugates and modified antibiotic molecules retain cytotoxic properties in vitro. Drug derivatives created by substituting C3' amino group possess a similar cytotoxic activity as non-modified drugs [4, 8, 23] . Here, we report a methotrexate-epirubicin conjugate strategy in which two different drugs and two different types of therapies are integrated. The formation of an amide bond between the MTX carboxylic group and the amine group of EPR resulted in hybrid MTX-EPR molecules. Synthetized conjugates combine combinatory therapy and targeted therapy, both of which are considered to be meaningful anticancer approaches. We expected that a combination of these two strategies possess a huge potential and can be highly beneficial in new anticancer drugs design. Molecular targets of exploited molecules are located in different cell compartments. MTX is an inhibitor of cytosolic enzyme (DHFR), whereas EPR's primary target is DNA located in the nucleus. Methotrexate serves a dual role in synthesized molecules. Apart from the high cytotoxicity it possesses, it has also targeting molecule properties, enabling selective cancer cell targeting through receptor-mediated endocytosis. EPR as free drug is transported into the cell through membrane diffusion, resulting in high cytotoxicity. A leading molecule like MTX can enhance EPR's selectivity, thereby limiting the side effects of applied therapy [18, 34] . The primary objective of our study was to investigate cytotoxic properties of the obtained MTX-EPR hybrid molecules. The antiproliferative activity of synthetized conjugates was evaluated in human tumor cell lines (LoVo, LoVo/Dx, MCF-7, MV-4-11) in vitro.
MaterIals and Methods
Methotrexate used in this research was purchased from EBEWE Pharma Ges. cells per well, 24 h before the addition of the tested compounds. Cells were exposed for 72 h to various concentrations (0.01, 0.1, 1, 10, µg/ml) of EPR, MTX or MTX-EPR conjugates. The MTT (MV-4-11) or SRB (MCF-7, LoVo, LoVo/Dx) assay was performed in order to evaluate the cytotoxic effect of the tested compounds as described previously [33] . The percent of proliferation inhibition was calculated according to the formula: % of proliferation inhibition =|[(ApAm)/(AcAm)×100(%)]-100(%)|, where: Ap absorbance of treated cells; Am absorbance of culture medium; Ac absorbance of control cells. The results were also calculated as the IC 50 (inhibitory concentration 50%), i.e. the dose of tested compound which inhibits the proliferation of cancer cells by 50%. IC 50 values were calculated for each experiment separately [21] and the mean value ± SD are presented in Table 1 . Each compound at a given concentration was tested in triplicates in a given experiment; each experiment was repeated 3-7 times. Statistical analysis was performed using STATISTICA version 10 (StatSoft Inc., USA 
dIscussIon
MTX and EPR are two well characterized and widely used chemotherapeutics in anticancer therapy [11, 22] . The study indicates that it is possible to synthetize new drugs by using already applied molecules. Combination of two different agents in one molecule creates an opportunity to overcome cytotoxic resistance; this approach is widely exploited in combinatory therapies. One of the main objectives of conjugates synthesized in this study was to enhance conjugate selectivity, which can be achieved by exploiting MTX as a leading molecule. We were hoping that after the loss of carboxylic groups, which are required for reduced folate carrier (RFC) internalization [35] , the main drug delivery mechanism will be FR-mediated endocytosis. The conresults MTX-EPR conjugates synthesis method is summarized in Figure 1 . First step of synthesis was MTX-NHS active esters formation that has been achieved by the presence of DCC and NHS in the reaction mixture. The resultant MTX-NHS esters can easily react with primary amine group of EPR aminosugar ring resulting in MTX-EPR hybrid molecules. MTX possesses two carboxylic groups: α and γ, both of which can be activated using DCC and NHS activation method. Therefore, a set of three target molecules can be created during the synthesis: monosubstituted derivatives (α, γ) and a disubstituted derivative.
Both derivatives (mono -and disubstituted) were purified using reversed phase chromatography (RPC) and the HPLC profile of obtained compounds is demonstrated in Figure 2 .
The structures of purified conjugates were confirmed by means of MS and MS/MS methods ( Figure 3 ). m/ z= 980.3435 corresponds to monosubstituted MTX derivative and peak with value m/z= 1505.5045 indicates disubstituted MTX derivative formation. Conjugates fragmentation data (mono -and disubstituted derivatives) show peaks characteristic for MTX and EPR molecules. We did not identify whether the α or γ carboxyl group was modified in the monosubstituted derivative. [26] and conjugate residence time inside the cell can be reduced. Modification through the α-carboxylic group can perturb interaction between MTX and DHFR [17] and reduce the capacity of MTX binding to FRs [12, 31] . EPR is transported into the cell through cell membrane diffusion [18] ; this transport can be disturbed after conjugation to MTX and the internalization of conjugate can be achieved only by receptor-mediated endocytosis. After internalization, the conjugates can be strongly bound to DHFR because of MTX high affinity to this enzyme and the drug can be arrested in the cytoplasm, thereby preventing penetration into the nucleus. Low conjugates activity in MCF-7 cell line suggests the lack of EPR activity in the synthesized molecules. The monosubstituted derivative shows similar IC 50 values for EPR sensitive LoVo cell line and EPR resistant LoVo/ Dx subline, also indicating the absence of EPR activity after internalization. However, disubstituted derivative 
